| Joshua Seay Kitchens, MD | |
|
1997 Barrett Ct, Henderson, KY 42420-2667 | |
| (270) 827-6662 | |
| (270) 826-8220 |
| Full Name | Joshua Seay Kitchens |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 1997 Barrett Ct, Henderson, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386974004 | NPI | - | NPPES |
| P01019922 | Other | KY | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R2141 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Anthony's Hospice Inc | Henderson, KY | Hospice |
| Methodist Hospital | Henderson, KY | Hospital |
| Owensboro Health Regional Hospital | Owensboro, KY | Hospital |
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Deaconess Clinic Inc | 3375610116 | 337 |
News Archive
A team of researchers led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, has shown for the first time that NDP1, a signaling molecule made from DHA, can trigger the production of a protective protein against toxic free radicals and injury in the brain and retina.
Researchers have discovered a key clue into the development of the pancreas and brain by studying rare patients born without a pancreas.
One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 4 days ago
| Entity Name | Owensboro Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235518242 PECOS PAC ID: 0648255034 Enrollment ID: O20040621000818 |
News Archive
A team of researchers led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, has shown for the first time that NDP1, a signaling molecule made from DHA, can trigger the production of a protective protein against toxic free radicals and injury in the brain and retina.
Researchers have discovered a key clue into the development of the pancreas and brain by studying rare patients born without a pancreas.
One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 4 days ago
| Entity Name | Deaconess Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891941688 PECOS PAC ID: 3375610116 Enrollment ID: O20081017000259 |
News Archive
A team of researchers led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, has shown for the first time that NDP1, a signaling molecule made from DHA, can trigger the production of a protective protein against toxic free radicals and injury in the brain and retina.
Researchers have discovered a key clue into the development of the pancreas and brain by studying rare patients born without a pancreas.
One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 4 days ago
| Entity Name | T & T Drugs |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578200788 PECOS PAC ID: 1951770981 Enrollment ID: O20221213002109 |
News Archive
A team of researchers led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, has shown for the first time that NDP1, a signaling molecule made from DHA, can trigger the production of a protective protein against toxic free radicals and injury in the brain and retina.
Researchers have discovered a key clue into the development of the pancreas and brain by studying rare patients born without a pancreas.
One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Seay Kitchens, MD Po Box 638706, Cincinnati, OH 45263-8706 Ph: (270) 827-7558 | Joshua Seay Kitchens, MD 1997 Barrett Ct, Henderson, KY 42420-2667 Ph: (270) 827-6662 |
News Archive
A team of researchers led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, has shown for the first time that NDP1, a signaling molecule made from DHA, can trigger the production of a protective protein against toxic free radicals and injury in the brain and retina.
Researchers have discovered a key clue into the development of the pancreas and brain by studying rare patients born without a pancreas.
One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?
Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.
› Verified 4 days ago
Michael A Roof, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 1305 N Elm St, Henderson, KY 42420 Phone: 270-827-7700 | |
Sheri Dawn Montgomery, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1305 N Elm St, Er, Henderson, KY 42420 Phone: 800-467-7766 | |
Kerry Conrad Gusler, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1305 N Elm St, Henderson, KY 42420 Phone: 270-827-7700 | |
Dr. David A Watkins, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1015 N Elm St, Henderson, KY 42420 Phone: 270-826-8009 Fax: 270-826-7010 | |
Nhan Huu Nguyen, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1015 North Elm Street, Henderson, KY 42420 Phone: 270-826-8009 Fax: 270-826-7010 | |
Mckenzie B Tucker, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1413 N Elm St Ste 201, Henderson, KY 42420 Phone: 270-827-8662 Fax: 270-826-8220 | |
Gerri L Moore, ARNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 340 Starlite Dr, Henderson, KY 42420 Phone: 270-844-8515 Fax: 270-844-8183 |